Edition:
India

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

130.78USD
13 Sep 2019
Change (% chg)

$0.35 (+0.27%)
Prev Close
$130.43
Open
$131.33
Day's High
$131.57
Day's Low
$129.97
Volume
1,574,916
Avg. Vol
2,124,192
52-wk High
$148.97
52-wk Low
$122.00

Latest Key Developments (Source: Significant Developments)

New Data From Spravato CIII Nasal Spray Phase 3 Studies Showed Rapid Reduction Of Depressive Symptoms
Monday, 9 Sep 2019 

Sept 9 (Reuters) - Johnson & Johnson ::NEW DATA FROM SPRAVATO™ (ESKETAMINE) CIII NASAL SPRAY PHASE 3 STUDIES SHOWED RAPID REDUCTION OF DEPRESSIVE SYMPTOMS IN ADULT PATIENTS WITH MAJOR DEPRESSIVE DISORDER WHO HAVE ACTIVE SUICIDAL IDEATION WITH INTENT.JANSSEN PHARMACEUTICAL COMPANIES - TREATMENT DIFFERENCE BETWEEN TWO GROUPS ON THIS SECONDARY ENDPOINT WAS NOT STATISTICALLY SIGNIFICANT.JANSSEN PHARMACEUTICAL COMPANIES - IN ASPIRE I & II TRIALS, SPRAVATO PLUS SOC WAS WELL-TOLERATED WITH NO NEW SAFETY SIGNAL.  Full Article

Janssen Announces U.S. FDA Breakthrough Therapy Designation For Investigational Prophylactic Respiratory Syncytial Virus
Tuesday, 3 Sep 2019 

Sept 3 (Reuters) - Janssen::JANSSEN ANNOUNCES U.S. FDA BREAKTHROUGH THERAPY DESIGNATION FOR INVESTIGATIONAL PROPHYLACTIC VACCINE FOR THE PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS IN OLDER ADULTS.JANSSEN - FDA BREAKTHROUGH THERAPY DESIGNATION WAS BASED ON CLINICAL DATA WITH JANSSEN'S PROPHYLACTIC RSV SENIOR VACCINE.  Full Article

Arrowhead Collaborator Janssen Begins Reef-1 Phase 2B Combination Study In Patients With Chronic Hepatitis B Infection
Wednesday, 28 Aug 2019 

Aug 28 (Reuters) - Arrowhead Pharmaceuticals Inc ::ARROWHEAD COLLABORATOR JANSSEN BEGINS REEF-1 PHASE 2B COMBINATION STUDY IN PATIENTS WITH CHRONIC HEPATITIS B INFECTION.ARROWHEAD PHARMACEUTICALS INC - ARROWHEAD EARNS $25 MILLION MILESTONE PAYMENT IN CONNECTION WITH TRIAL INITIATION.ARROWHEAD PHARMACEUTICALS INC - JANSSEN HAS BEGUN DOSING IN REEF-1 PHASE 2B COMBINATION STUDY IN PATIENTS WITH CHRONIC HEPATITIS B INFECTION.  Full Article

Pharma Mar And Janssen Enter Into New Licensing Agreement For Yondelis In US
Monday, 26 Aug 2019 

Aug 26 (Reuters) - Pharma Mar SA ::PHARMA MAR AND JANSSEN HAVE ENTERED INTO A NEW LICENSING AGREEMENT FOR YONDELIS IN US.ALSO ENTERS INTO MASTER PRODUCT TRANSFER AGREEMENT ON YONDELIS RIGHTS IN THE REST OF THE TERRITORIES LICENSED TO JANSSEN.JANSSEN WILL RETAIN RIGHTS TO EXCLUSIVELY MARKET AND DISTRIBUTE YONDELIS IN USA.MILESTONES AND ROYALTIES ON JANSSEN’S U.S. NET SALES OF PRODUCT REMAIN THE SAME AS IN THE 2001 LICENSING AGREEMENT.TO MAINTAIN EXCLUSIVE PRODUCTION RIGHTS OF ACTIVE INGREDIENT, WHICH WILL BE SUPPLIED TO JANSSEN FOR CLINICAL AND COMMERCIAL USE.MASTER PRODUCT TRANSFER AGREEMENT WILL ALLOW PHARMAMAR TO DISTRIBUTE YONDELIS IN OVER 40 ADDITIONAL COUNTRIES WHERE THE PRODUCT HAS ALREADY BEEN APPROVED.  Full Article

Johnson & Johnson Reports Q2 Adjusted EPS Of $2.58
Tuesday, 16 Jul 2019 

July 16 (Reuters) - Johnson & Johnson ::REPORTS 2019 SECOND-QUARTER RESULTS.Q2 ADJUSTED EARNINGS PER SHARE $2.58.Q2 EARNINGS PER SHARE $2.08.Q2 EARNINGS PER SHARE ESTIMATE $2.46 -- REFINITIV IBES DATA.Q2 REVENUE $20.6 BILLION VERSUS REFINITIV IBES ESTIMATE OF $20.29 BILLION.OPERATIONAL SALES GUIDANCE INCREASED DUE TO STRENGTH OF BUSINESS; EPS GUIDANCE RANGE MAINTAINED.QTRLY OPERATIONAL GROWTH OF 1.6% AND ADJUSTED OPERATIONAL GROWTH OF 3.7%."PIPELINES CONTINUE TO PROGRESS WITH LAUNCH OF NEW PRODUCTS AND SEVERAL REGULATORY SUBMISSIONS AND APPROVALS".QTRLY PHARMACEUTICAL WORLDWIDE OPERATIONAL SALES, EXCLUDING NET IMPACT OF ACQUISITIONS AND DIVESTITURES GREW 4.4%.QTRLY GAAP NET LITIGATION EXPENSE $409 MILLION VERSUS $703 MILLION.SEES FY 2019 ADJUSTED OPERATIONAL SALES CHANGE VERSUS. PRIOR YEAR 3.2% - 3.7%.SEES FY ADJUSTED EPS $8.53 TO $8.63.QTRLY WORLDWIDE REMICADE SALES $1,107 MILLION VERSUS $1,320 MILLION.SEES FY 2019 OPERATIONAL SALES $82.4 BILLION TO $83.2 BILLION.QTRLY WORLDWIDE IMBRUVICA SALES $831 MILLION VERSUS $620 MILLION.SEES FY 2019 ESTIMATED REPORTED SALES $80.8 BILLION TO $81.6 BILLION.FY2019 EARNINGS PER SHARE VIEW $8.60, REVENUE VIEW $81.22 BILLION -- REFINITIV IBES DATA.QTRLY WORLDWIDE ZYTIGA SALES $698 MILLION VERSUS $909 MILLION.QTRLY WORLDWIDE STELARA SALES $1,558 MILLION VERSUS $1,341 MILLION.  Full Article

Johnson & Johnson Sets Quarterly Cash Dividend Of $0.95 Per Share
Monday, 15 Jul 2019 

July 15 (Reuters) - Johnson & Johnson ::JOHNSON & JOHNSON ANNOUNCES QUARTERLY DIVIDEND FOR THIRD QUARTER 2019.SETS QUARTERLY CASH DIVIDEND OF $0.95PER SHARE.  Full Article

J&J Poised To Test Experimental HIV Vaccine In U.S. And Europe, Starting Later This Year - Bloomberg
Friday, 12 Jul 2019 

July 12 (Reuters) - :JOHNSON & JOHNSON IS POISED TO TEST AN EXPERIMENTAL HIV VACCINE IN THE U.S. AND EUROPE, STARTING LATER THIS YEAR - BLOOMBERG.  Full Article

Tracon Pharmaceuticals Provides Update On Phase 1/2 Trial Of Trc253
Tuesday, 2 Jul 2019 

July 2 (Reuters) - TRACON Pharmaceuticals Inc ::TRACON PHARMACEUTICALS PROVIDES UPDATE ON PHASE 1/2 TRIAL OF TRC253 IN PATIENTS WITH METASTATIC CASTRATE RESISTANT PROSTATE CANCER.TRACON PHARMACEUTICALS INC - PHASE 1 DATA PUBLISHED IN ASCO PROCEEDINGS DETERMINED RECOMMENDED PHASE 2 DOSE.TRACON PHARMACEUTICALS INC - ADDITIONAL COHORT OF PATIENTS WITH A SPECIFIC ANDROGEN RECEPTOR POINT MUTATION ADDED TO ONGOING PHASE 2 STUDY.TRACON PHARMACEUTICALS INC - PHASE 2 DATA EXPECTED IN 2(ND) HALF 2020; POTENTIAL FOR $45 MILLION OPT-IN PAYMENT FROM JANSSEN.TRACON PHARMACEUTICALS INC - TRC253 WAS WELL-TOLERATED AND NO DRUG-RELATED SERIOUS ADVERSE EVENTS WERE REPORTED.  Full Article

Janssen Receives Positive CHMP Opinion Recommending Expanded Use Of Imbruvica
Friday, 28 Jun 2019 

June 28 (Reuters) - JANSSEN::JANSSEN RECEIVES POSITIVE CHMP OPINION RECOMMENDING EXPANDED USE OF IMBRUVICA®▼(IBRUTINIB) IN TWO INDICATIONS IN EUROPE.JANSSEN - ONE RECOMMENDATION IS FOR USE OF IBRUTINIB IN COMBINATION WITH OBINUTUZUMAB IN ADULT PATIENTS WITH PREVIOUSLY UNTREATED CLL.JANSSEN - SECOND RECOMMENDATION IS FOR USE OF IBRUTINIB PLUS RITUXIMAB FOR TREATMENT OF ADULT PATIENTS WITH WALDENSTRÖM'S MACROGLOBULINEMIA.  Full Article

Genmab Announces U.S. FDA Approval Of Darzalex In Combination With Lenalidomide And Dexamethasone
Thursday, 27 Jun 2019 

June 27 (Reuters) - Genmab A/S ::GENMAB ANNOUNCES U.S. FDA APPROVAL OF DARZALEX® (DARATUMUMAB) IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN FRONTLINE MULTIPLE MYELOMA.GENMAB - APPROVAL OF DARZALEX (DARATUMUMAB) IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE BASED ON PHASE III MAIA STUDY.  Full Article

Photo

Bayer hires former J&J executive for more pharma deals

FRANKFURT Bayer said it hired Johnson & Johnson executive Marianne De Backer to manage acquisitions and licensing deals at its drugs unit, as the German drugmaker turns to outside sources to boost its development pipeline.